Boehringer Ingelheim is paying $358 million upfront to claim options on up to six antibody-drug conjugates (ADCs) and T cell ...

As an oncologist with more than 25 years of experience across clinical care, research, drug and device development, and ...

Businesses are finding that AI is a great leveller. Organisations with mature digital infrastructures can use AI to unlock ...

Novo has raised its financial guidance for 2026 on the back of rising sales of its oral weight-loss therapy Wegovy, which ...

Theramex, a London, UK-based specialty pharma company focusing on women's health, is changing hands in a deal reportedly ...

Hard on the heels of a £1 billion investment package by pharma companies in last week's UK Budget, AbbVie has pledged another ...

The BioInnovation Institute (BII) has expanded a network striving to develop treatments for cardiometabolic diseases and ...

Bayer's pharma unit has reached a "turning point" in its growth trajectory as sales of new medicines rose 6.4% in the third quarter, according to chief executive Bill Anderson. The rise in pharma ...

UK contract development and manufacturing organisation (CDMO) Oxford BioMedica confirmed this morning that it has received an unsolicited approach from private equity group EQT about a possible ...

Eli Lilly has added another arrow to the quiver of its new diabetes and weight-loss therapy retatrutide, comprehensively outperforming Novo's rival Ozempic in a head-to-head trial. Results from the ...

It’s been almost a decade since Japanese pharma company Daiichi Sankyo began its dramatic pivot from cardiovascular health into antibody-drug conjugates. For Daiichi Sankyo, it’s hard to argue that ...

Axsome Therapeutics' Auvelity has become the first non-antipsychotic therapy for agitation in patients with Alzheimer's disease to be approved by the FDA, which called the drug a "significant ...